Cart
sales@molnova.com
Eltoprazine
CAS No. 98224-03-4
Eltoprazine( DU-28853 )
Catalog No. M16892 CAS No. 98224-03-4
An antiaggressive agent that acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEltoprazine
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn antiaggressive agent that acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.
-
DescriptionAn antiaggressive agent that acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.Schizophrenia Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsDU-28853
-
PathwayGPCR/G Protein
-
Target5-HT Receptor
-
Recptor5-HT Receptor
-
Research AreaNeurological Disease
-
IndicationSchizophrenia
Chemical Information
-
CAS Number98224-03-4
-
Formula Weight220.2676
-
Molecular FormulaC12H16N2O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC1CN(CCN1)C2=C3C(=CC=C2)OCCO3.Cl
-
Chemical NamePiperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sijbesma H, et al. Eur J Pharmacol. 1990 Feb 20;177(1-2):55-66.
2. Jo?ls M, et al. J Pharmacol Exp Ther. 1990 Apr;253(1):284-9.
3. Mos J, et al. Eur J Pharmacol. 1992 Mar 3;212(2-3):295-8.
molnova catalog
related products
-
Felcisetrag
Felcisetrag (TD-8954) is a potent and selective orally active 5-HT4 agonist with gastrointestinal prokinetic properties.
-
Relenopride
Relenopride (YKP 10811) is a selective 5-HT4 receptor agonist that promotes intestinal motility and is used in the study of intestinal disorders.
-
Alosetron
A potent and selective 5-HT3 receptor antagonist has been shown to be beneficial in the treatment of irritable bowel syndrome.
